{"id":55601,"date":"2026-01-27T17:38:32","date_gmt":"2026-01-27T09:38:32","guid":{"rendered":"https:\/\/flcube.com\/?p=55601"},"modified":"2026-01-27T17:38:33","modified_gmt":"2026-01-27T09:38:33","slug":"ascp-launches-250k-grants-for-mcrc-biomarker-testing-with-pfizer-asco","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55601","title":{"rendered":"ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO"},"content":{"rendered":"\n

The American Society for Clinical Pathology (ASCP)<\/strong>, in collaboration with Pfizer<\/strong> (NYSE:\u202fPFE<\/a>) and with participation from the American Society of Clinical Oncology (ASCO)<\/strong>, announced a Request for Proposals (RFP)<\/strong> to fund Quality Improvement (QI) grant projects<\/strong> up to USD\u202f250,000 each<\/strong>. The initiative targets improved biomarker testing to support frontline treatment selection in metastatic colorectal cancer (mCRC)<\/strong>.<\/p>\n\n\n\n

Program Structure & Funding<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Administering Body<\/strong><\/td>ASCP<\/td><\/tr>
Funding Partner<\/strong><\/td>Pfizer (NYSE:\u202fPFE)<\/td><\/tr>
Advisory Partner<\/strong><\/td>ASCO<\/td><\/tr>
Grant Amount<\/strong><\/td>Up to USD\u202f250,000 per project<\/td><\/tr>
Focus Area<\/strong><\/td>Biomarker testing optimization for mCRC frontline treatment<\/td><\/tr>
Target Institutions<\/strong><\/td>Community\u2011based healthcare facilities<\/td><\/tr>
Key Biomarkers<\/strong><\/td>RAS (KRAS\/NRAS), BRAF, HER2 amplification, MSI\/MMR status<\/td><\/tr>
Guideline Alignment<\/strong><\/td>NCCN guidelines<\/td><\/tr>
RFP Launch<\/strong><\/td>26\u202fJan\u202f2026<\/td><\/tr>
Program Duration<\/strong><\/td>Multi\u2011year initiative<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Objectives<\/h2>\n\n\n\n